Semaglutide Achieves 90% Weight Loss Success Rate in Hypothalamic Obesity After Brain Tumor Surgery | Research

The takeaway

In 14 patients with hypothalamic obesity after craniopharyngioma surgery, semaglutide produced significant weight loss (108.9 to 96.1 kg over 6 months) with 90% achieving >5% weight loss, while the control group gained weight.

90% responder rate
Proportion of semaglutide-treated patients achieving >5% weight loss at 6 months — remarkable for hypothalamic obesity, the most treatment-resistant form of obesity

What the researchers found

In the semaglutide group (n=14), weight decreased significantly from 108.9 ± 20.9 kg to 100.8 ± 20.2 kg at 3 months (p < 0.001) and to 96.1 ± 23.1 kg at 6 months (p < 0.001) — a total loss of ~12.8 kg. At 3 months, 64.3% achieved >5% weight loss; at 6 months, this rose to 90%. The control group (n=9) on lifestyle intervention alone experienced weight gain over the same period.

This is particularly notable because hypothalamic obesity is driven by brain damage rather than behavioral factors, and most weight loss interventions are ineffective in this population.

Why it matters

Hypothalamic obesity after brain tumor surgery is one of the most treatment-resistant forms of obesity — patients have a damaged appetite control center and most weight management strategies fail. This study provides the first evidence that semaglutide can produce meaningful weight loss in this population, offering hope for patients who previously had almost no effective treatment options.

How the study worked

Prospective clinical study at Peking Union Medical College Hospital (March 2023 to October 2024). 23 obese patients post-craniopharyngioma surgery were divided into semaglutide treatment (n=14) and lifestyle intervention control (n=9). Weight, BMI, waist circumference, blood glucose, and lipid profiles were measured at baseline, 3 months, and 6 months. Registered trial (ChiCTR2400094933).

What this study cannot tell us

Small sample size (n=23 total, 14 treated). Non-randomized assignment to groups may introduce selection bias. The control group was smaller (n=9) and may not be fully comparable. Only 6 months of follow-up — long-term weight maintenance after hypothalamic damage is unknown. No blinding of patients or investigators. The study was conducted at a single center in China.

How to read the evidence

This is a small, non-randomized prospective clinical study (n=23). While the results are striking — especially the contrast with the weight-gaining control group — the lack of randomization, small sample, and single-center design limit the strength of the evidence. Larger randomized trials are needed.

When this study was published

Published in 2025 with data from 2023-2024, this is among the first clinical studies evaluating semaglutide specifically for hypothalamic obesity — a niche but devastating condition.

The bigger picture

This study tests GLP-1 receptor agonists in one of the most challenging obesity scenarios — where the brain's appetite center is physically damaged. The success of semaglutide here suggests that GLP-1R activation works through pathways partially independent of hypothalamic appetite regulation, or that it can compensate for hypothalamic damage. This expands the potential application of GLP-1 drugs to neurologically-driven obesity syndromes.

Questions still open

Does semaglutide maintain weight loss beyond 6 months in hypothalamic obesity, or does weight regain occur?
What mechanism allows semaglutide to work when the hypothalamus is damaged — are brainstem or peripheral GLP-1 receptors sufficient?
Could semaglutide be started immediately after craniopharyngioma surgery to prevent hypothalamic obesity from developing?

Common questions

What is hypothalamic obesity and why is it so hard to treat?

The hypothalamus is the brain's appetite control center. When it's damaged during brain tumor surgery (like craniopharyngioma removal), patients lose their ability to feel full and regulate energy balance, leading to severe, uncontrollable weight gain. Traditional weight loss strategies — diet, exercise, even most medications — typically don't work because the fundamental problem is brain damage, not behavior.

Why is semaglutide working when other treatments fail?

GLP-1 receptors exist not only in the hypothalamus but also in other brain regions and throughout the body. Semaglutide may be able to reduce appetite and improve metabolism through these alternative pathways, bypassing the damaged hypothalamus. The 90% success rate in this study suggests the drug can partially compensate for the brain damage driving this form of obesity.

Read the original research

The Efficacy of Semaglutide on Hypothalamic Obesity Caused by Craniopharyngioma Surgery.

Clinical endocrinology, 103(3), 359-365

View on PubMed ↗Publisher’s paper ↗

Citation

Wang, Xi; Ma, Hailu; Wang, Fang; Long, Hongmei; Li, Chenyang; Nie, Min; Han, Qin; Mao, Jiangfeng; Wu, Xueyan. (2025). The Efficacy of Semaglutide on Hypothalamic Obesity Caused by Craniopharyngioma Surgery.. Clinical endocrinology, 103(3), 359-365. https://doi.org/10.1111/cen.15262